These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11524026)

  • 1. Methylphenidate (OROS formulation).
    Keating GM; McClellan K; Jarvis B
    CNS Drugs; 2001; 15(6):495-500; discussion 501-3. PubMed ID: 11524026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate improves aspects of executive function in African American children with ADHD.
    Hazel-Fernandez LA; Klorman R; Wallace JM; Cook S
    J Atten Disord; 2006 May; 9(4):582-9. PubMed ID: 16648225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired neural reward processing in children and adolescents with reactive attachment disorder: A pilot study.
    Mizuno K; Takiguchi S; Yamazaki M; Asano M; Kato S; Kuriyama K; Watanabe Y; Sadato N; Tomoda A
    Asian J Psychiatr; 2015 Oct; 17():89-93. PubMed ID: 26310381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catecholaminergic modulation of meta-learning.
    Cook JL; Swart JC; Froböse MI; Diaconescu AO; Geurts DE; den Ouden HE; Cools R
    Elife; 2019 Dec; 8():. PubMed ID: 31850844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018.
    Weibel S; Lopez R; Micoulaud-Franchi JA; Bioulac S; Lecendreux M; Bertschy G
    Br J Clin Pharmacol; 2019 Jan; 85(1):273-274. PubMed ID: 30255566
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
    Katzman MA; Sternat T
    CNS Drugs; 2014 Nov; 28(11):1005-33. PubMed ID: 25120227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.
    Markowitz JS; DeVane CL; Pestreich LK; Patrick KS; Muniz R
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):687-98. PubMed ID: 17201613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC; Nutt DJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release methylphenidate (Ritalin LA).
    Lyseng-Williamson KA; Keating GM
    Drugs; 2002; 62(15):2251-9; discussion 2260-1. PubMed ID: 12381228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
    Eagling VA; Tjia JF; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of cytochrome P450-3A inhibition by ketoconazole.
    Greenblatt DJ; Zhao Y; Venkatakrishnan K; Duan SX; Harmatz JS; Parent SJ; Court MH; von Moltke LL
    J Pharm Pharmacol; 2011 Feb; 63(2):214-21. PubMed ID: 21235585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.
    Patrick KS; González MA; Straughn AB; Markowitz JS
    Expert Opin Drug Deliv; 2005 Jan; 2(1):121-43. PubMed ID: 16296740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classics in Chemical Neuroscience: Methylphenidate.
    Wenthur CJ
    ACS Chem Neurosci; 2016 Aug; 7(8):1030-40. PubMed ID: 27409720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not All Generic Concerta Is Created Equal: Comparison of OROS Versus Non-OROS for the Treatment of ADHD.
    Lally MD; Kral MC; Boan AD
    Clin Pediatr (Phila); 2016 Nov; 55(13):1197-1201. PubMed ID: 26467563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.
    Conley R; Gupta SK; Sathyan G
    Curr Med Res Opin; 2006 Oct; 22(10):1879-92. PubMed ID: 17022845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.
    Menza M; Marin H; Kaufman K; Mark M; Lauritano M
    J Neuropsychiatry Clin Neurosci; 2004; 16(3):315-9. PubMed ID: 15377738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylphenidate : a treatment for Parkinson's disease?
    Devos D; Moreau C; Delval A; Dujardin K; Defebvre L; Bordet R
    CNS Drugs; 2013 Jan; 27(1):1-14. PubMed ID: 23160937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.